(Q51319077)

3 April 2018

title

Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer. (English)

1 reference

3 April 2018

1 reference

Onder Tonyali

1

1 reference

3 April 2018

Ugur Coskun

2

1 reference

3 April 2018

Nur Sener

3

1 reference

3 April 2018

Mevlude Inanc

4

1 reference

3 April 2018

Tulay Akman

5

1 reference

3 April 2018

Berna Oksuzoglu

6

1 reference

3 April 2018

Nuriye Yildirim Ozdemir

7

1 reference

3 April 2018

Dogan Yazilitas

8

1 reference

3 April 2018

Mustafa Benekli

9

1 reference

3 April 2018

Aytug Uner

10

1 reference

3 April 2018

Deniz Yamac

11

1 reference

3 April 2018

Umut Demirci

12

1 reference

3 April 2018

Ramazan Yildiz

13

1 reference

3 April 2018

Halit Karaca

14

1 reference

3 April 2018

Olcun Umit Unal

15

1 reference

3 April 2018

Oznur Bal

16

1 reference

3 April 2018

Mahmut Gumus

17

1 reference

3 April 2018

Suleyman Buyukberber

18

1 reference

3 April 2018

Anatolian Society of Medical Oncology (ASMO)

19

1 reference

3 April 2018

publication date

10 August 2012

1 reference

3 April 2018

Journal of Cancer Research and Clinical Oncology

published in

1 reference

3 April 2018

volume

138

1 reference

3 April 2018

issue

12

1 reference

3 April 2018

page(s)

2145-2151

1 reference

3 April 2018

Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1296-X

Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1296-X

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1296-X

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1296-X

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1296-X

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1296-X

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1296-X

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1296-X

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1296-X

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1296-X

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1296-X

Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1296-X

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1296-X

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1296-X

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1296-X

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1296-X

Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1296-X

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22878681

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

1 reference

https://pubmed.ncbi.nlm.nih.gov/22878681

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00432-012-1296-X

1 reference

3 April 2018

1 reference

3 April 2018